Comparative Pharmacology
Head-to-head clinical analysis: PHRENILIN WITH CAFFEINE AND CODEINE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHRENILIN WITH CAFFEINE AND CODEINE versus WESTADONE.
PHRENILIN WITH CAFFEINE AND CODEINE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination analgesic; butalbital is a barbiturate that potentiates GABA-A activity; acetaminophen inhibits cyclooxygenase (COX) and modulates cannabinoid receptors; caffeine is a nonselective adenosine receptor antagonist; codeine is a prodrug converted to morphine, a mu-opioid agonist.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1-2 capsules orally every 4 hours as needed, not to exceed 8 capsules per day. Each capsule contains butalbital 50 mg, caffeine 40 mg, and codeine phosphate 30 mg.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Butalbital: 35–50 hours; codeine: 2.5–3.5 hours; caffeine: 4–6 hours (adults), prolonged in liver disease. Clinical context: butalbital's long half-life leads to accumulation with repeated dosing; codeine's short half-life requires frequent dosing.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal: butalbital ~60% unchanged; codeine ~90% as metabolites (free and conjugated morphine, norcodeine); caffeine <2% unchanged, ~80% as metabolites (paraxanthine, theobromine, theophylline) via renal excretion. Biliary/fecal: minimal.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist